Designer drugs: FDHA brings further psychoactive substances under control

Swissmedic

REGULATORY UPDATE

Published: 11/10/2026Detected: 11/10/2026

Summary preview

Brings additional psychoactive “designer drugs” under Swiss control, expanding regulatory coverage to new substances with potential public-health and abuse risks.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account

safety

psychiatry

#designer drugs

#psychoactive substances

#drug control

#import compliance

#distribution

Official Source Document
Source Verified

Access the original document directly from SWISSMEDIC.

View Official Document

More from Swissmedic

Get Swissmedic alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

Security

Privacy Policy

Terms of Service

Not affiliated with the FDA, EMA, or Health Canada.

Summary preview

Get the full analysis, free

Official Source Document Source Verified

More from Swissmedic

Get Swissmedic alerts in your inbox as they are published.

Official Source Document
Source Verified